EPAS1 and nonpapillary renal cell carcinoma: Therefore, the level of HIF-2α expression may represent a potential efficacy biomarker for the CX-4945/KU-60019 treatment (a higher baseline pre-treatment level of HIF-2α would be predictive of response for patients with ccRCC).